Adrenal atrophy physical examination: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Adrenal atrophy}} | {{Adrenal atrophy}} | ||
{{CMG}}; {{AE}} {{MHP}} | |||
==Overview== | |||
In the physical examination the patients may have hypotension, hyperpigmentation, depigmentation in autoimmune cases. | |||
==Physical examination== | |||
In the physical examination the patients may have: | In the physical examination the patients may have: | ||
*Hypotension, mainly with postural dizziness or syncope. | *Hypotension, mainly with postural dizziness or syncope. | ||
*Hyperpigmentation, which is evident in nearly all patients with primary adrenal insufficiency, is the most characteristic physical finding. | *Hyperpigmentation, which is evident in nearly all patients with primary adrenal insufficiency, is the most characteristic physical finding. | ||
*Patchy, often bilaterally symmetrical areas of depigmented skin (vitiligo), the result of autoimmune destruction of dermal melanocytes, occur on the trunk or extremities in 10 to 20 percent of patients | *Patchy, often bilaterally symmetrical areas of depigmented skin (vitiligo), the result of autoimmune destruction of dermal melanocytes, occur on the trunk or extremities in 10 to 20 percent of patients | ||
with autoimmune but not those with other causes of adrenal atrophy. | with autoimmune but not those with other causes of adrenal atrophy.<ref name="pmid10084558">{{cite journal |vauthors=Abdu TA, Elhadd TA, Neary R, Clayton RN |title=Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease |journal=J Clin Endocrinol Metab |volume=84 |issue=3 |pages=838–43 |date=March 1999 |pmid=10084558 |doi=10.1210/jcem.84.3.5535 |url=}}</ref><ref name="pmid19382991">{{cite journal |vauthors=Husebye ES, Perheentupa J, Rautemaa R, Kämpe O |title=Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I |journal=J Intern Med |volume=265 |issue=5 |pages=514–29 |date=May 2009 |pmid=19382991 |doi=10.1111/j.1365-2796.2009.02090.x |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 03:30, 5 February 2022
|
Adrenal atrophy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Adrenal atrophy physical examination On the Web |
|
American Roentgen Ray Society Images of Adrenal atrophy physical examination |
|
Risk calculators and risk factors for Adrenal atrophy physical examination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]
Overview
In the physical examination the patients may have hypotension, hyperpigmentation, depigmentation in autoimmune cases.
Physical examination
In the physical examination the patients may have:
- Hypotension, mainly with postural dizziness or syncope.
- Hyperpigmentation, which is evident in nearly all patients with primary adrenal insufficiency, is the most characteristic physical finding.
- Patchy, often bilaterally symmetrical areas of depigmented skin (vitiligo), the result of autoimmune destruction of dermal melanocytes, occur on the trunk or extremities in 10 to 20 percent of patients
with autoimmune but not those with other causes of adrenal atrophy.[1][2]
References
- ↑ Abdu TA, Elhadd TA, Neary R, Clayton RN (March 1999). "Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease". J Clin Endocrinol Metab. 84 (3): 838–43. doi:10.1210/jcem.84.3.5535. PMID 10084558.
- ↑ Husebye ES, Perheentupa J, Rautemaa R, Kämpe O (May 2009). "Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I". J Intern Med. 265 (5): 514–29. doi:10.1111/j.1365-2796.2009.02090.x. PMID 19382991.